R&D Trends

Luxcel Biosciences , Axiogenesis, BMG LABTECH to develop cell metabolism analysis platform

Thursday, February 16, 2017

Three European technology SME’s, together with two research institutions, Oxford University and Imperial College London, have been awarded €2.5 million funding from the European commission under the H2020 Fast Track to Innovation (FTI) pilot, to develop and launch a cell metabolism analysis platform that is predicted to be part of routine in vitro cell biology and drug development. 

[Read More]

Boehringer Ingelheim, Weill Cornell Medicine partner on next generation COPD treatments

Wednesday, February 15, 2017

Boehringer Ingelheim has announced a collaboration with Weill Cornell Medicine to identify new treatment approaches for chronic obstructive pulmonary disease (COPD) in order to develop novel treatments that could possibly halt or even reverse the progression of the disease process. The new, three-year collaboration combines Weill Cornell Medicine’s Department of Genetic Medicine’s unique understanding of chronic airway diseases and experience in the investigation of novel therapeutic concepts for airway repair with Boehringer Ingelheim’s expertise in the discovery and development of new therapies for respiratory diseases. This collaboration is the second collaboration between Boehringer Ingelheim and Weill Cornell Medicine, following prior work in inflammatory bowel disease (IBD).

[Read More]

RCSI, Almac partner on target therapy-resistant cancer tumors

Wednesday, February 15, 2017

RCSI (Royal College of Surgeons in Ireland) and Almac Discovery, a biopharmaceutical company focused on discovering and identifying innovative therapeutics for the treatment of cancer, have announced a major research collaboration that aims to gain a new understanding of how to target tumor cells that are resistant to cancer therapies and cause cancer to spread to other parts of the body. The project will explore the potential of a drug, based on initial research by RCSI’s Professor Tracy Robson and developed by Almac Discovery, which is currently undergoing a phase I dose escalation trial for patients with solid tumors. It is expected that the trial will be expanded in a biomarker selected patient population within ovarian cancer, however the drug, ALM201, has the potential to treat a range of other cancers.

[Read More]

Incyte, Agenus amend collaboration agreement

Wednesday, February 15, 2017

Incyte and Agenus have amended the License, Development and Commercialization Agreement that was originally entered into January 9, 2015. The amended agreement converts the ongoing GITR and OX40 antibody programs from co-funded development and profit-sharing arrangements to royalty-bearing programs, with Incyte now responsible for funding and conducting global development and commercialization. Should candidates from either of these two programs be approved, Agenus would now become eligible to receive 15% royalties on global net sales of each approved product.

[Read More]

GeNeuro, NIH partner to develop novel antibody treatment for ALS

Friday, February 10, 2017

GeNeuro, a biopharmaceutical company developing new treatments for neurological disorders and autoimmune diseases, including multiple sclerosis (MS), has announced the signing of a Cooperative Research and Development Agreement (CRADA) with The National Institute of Neurological Disorders and Stroke (NINDS), part of the NIH, to develop novel therapeutic antibodies for the treatment of amyotrophic lateral sclerosis (ALS). The research will evaluate the ability of these antibodies to neutralise a potential causal factor of ALS, the envelope protein of HERV-K (a family of Human Endogenous Retroviruses, HERVs). 

[Read More]